25.09.2017 • News • Elaine Burridge • Mitsubishi • Mergers & Acquisitions (M&A)

NeuroDerm Approves Merger with Mitsubishi

(c) Andrew S/Shutterstock
(c) Andrew S/Shutterstock

All of NeuroDerm’s shareholders have voted to approve the takeover by Japan’s Mitsubishi Tanabe Pharma. The merger was officially agreed on Jul. 24.

NeuroDerm said that all antitrust approvals and clearances have now been obtained and it expects the transaction to complete in mid-October, following the expiration of a mandatory 30-day waiting period following shareholder approval under Israeli law.

At the merger’s closing, NeuroDerm shareholders will have the right to receive $39 in exchange for each ordinary share.

As part of the deal, MT Porto, a wholly owned subsidiary of Mitsubishi Tanabe, will also be merged into NeuroDerm.

The Rehovot-based pharma company is developing drug-device combinations for central nervous system (CNS) disorders. Its lead product is ND0612 for treating Parkinson's disease, for which NeuroDerm expects to submit regulatory applications in Europe by the end of 2018.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Top-Feature